On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
BUSINESS
4 More Products Recalled over Flawed Testing at Kyowa CritiCare
Voluntary recalls were announced for four more soft bag preparations on August 3 over flawed testing at Kyowa CritiCare, which takes on contract manufacturing for many companies, bringing the total number of affected products to 38. Subject to the new…
To read the full story
Related Article
- 2 More Soft Bag Products Recalled Over Flawed Testing at Kyowa CritiCare
December 3, 2020
- Kyowa CritiCare Resumes Production of Soft Bag Products
October 14, 2020
- 1 More Soft Bag Product Recalled Over Flawed Testing at Kyowa CritiCare
October 8, 2020
- Flawed Testing at Kyowa CritiCare Costs 2 More Product Recalls
September 4, 2020
- 4 Add’l Products Recalled over Flawed Testing at Kyowa CritiCare
August 20, 2020
- 28 Products from 10-Plus Firms Recalled due to Flawed Tests at Kyowa CritiCare
July 31, 2020
BUSINESS
- Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
- Pfizer Launching Joint Research Aimed at Broadening Use of Medical Big Data
January 21, 2021
- Enhertu Approved for Breast Cancer in Europe: Daiichi Sankyo/AZ
January 21, 2021
- Will Cymbalta, E Keppra Face Generic Competition This Year? Vesicare, Aloxi Too?
January 20, 2021
- Sanofi Files Pompe Therapy Avalglucosidase Alfa in Japan
January 20, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…